Literature DB >> 25421283

Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Qiang Gao1, Xiao-Ying Wang1, Jian Zhou2, Jia Fan2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25421283     DOI： 10.1038/nrclinonc.2014.122-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  13 in total

1.  Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Fei-Xiang Wu; Hang Li
Journal:  Tumour Biol       Date:  2014-09-09

2.  The ALPPS procedure for hepatocellular carcinoma.

Authors:  G Vennarecci; A Laurenzi; G B Levi Sandri; E Busi Rizzi; M Cristofaro; M Montalbano; P Piselli; A Andreoli; G D'Offizi; G M Ettorre
Journal:  Eur J Surg Oncol       Date:  2014-04-13       Impact factor: 4.424

3.  Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.

Authors:  Kwang-Hyub Han; Masatochi Kudo; Sheng-Long Ye; Jong Young Choi; Roonni Tung-Ping Poon; Jinsil Seong; Joong-Won Park; Takafumi Ichida; Jin Wook Chung; Pierce Chow; Ann-Lii Cheng
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

4.  When to perform hepatic resection for intermediate-stage hepatocellular carcinoma.

Authors:  Alessandro Cucchetti; Benjamin Djulbegovic; Athanasios Tsalatsanis; Alessandro Vitale; Iztok Hozo; Fabio Piscaglia; Matteo Cescon; Giorgio Ercolani; Francesco Tuci; Umberto Cillo; Antonio Daniele Pinna
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

5.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

Review 6.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

7.  Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma.

Authors:  Edith Y Ho; Myrna L Cozen; Hui Shen; Robert Lerrigo; Erica Trimble; James C Ryan; Carlos U Corvera; Alexander Monto
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

8.  Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT.

Authors:  Lei Yin; Hui Li; Ai-Jun Li; Wan Yee Lau; Ze-Ya Pan; Eric C H Lai; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Hepatol       Date:  2014-03-17       Impact factor: 25.083

Review 9.  Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.

Authors:  Luigi Bolondi; Andrew Burroughs; Jean-François Dufour; Peter R Galle; Vincenzo Mazzaferro; Fabio Piscaglia; Jean Luc Raoul; Bruno Sangro
Journal:  Semin Liver Dis       Date:  2013-02-08       Impact factor: 6.115

Review 10.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059
View more
  18 in total

1.  Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

2.  OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.

Authors:  Dan Wu; Xufang Yang; Huiming Peng; Dongmin Guo; Weiling Zhao; Chen Zhao; Xiaobo Zhou
Journal:  Carcinogenesis       Date:  2017-09-01       Impact factor: 4.944

3.  The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.

Authors:  Yan An; Yanfang Guan; Yaping Xu; Yingxin Han; Chi Wu; Chaohui Bao; Boping Zhou; Haiyan Wang; Mingxia Zhang; Weilong Liu; Lin Qiu; Zeguang Han; Yongsheng Chen; Xuefeng Xia; Jiayin Wang; Zhentian Liu; Wanqiu Huang; Xin Yi; Jian Huang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

Review 4.  Liver resection for intermediate hepatocellular carcinoma.

Authors:  Peng-Sheng Yi; Ming Zhang; Ji-Tong Zhao; Ming-Qing Xu
Journal:  World J Hepatol       Date:  2016-05-18

Review 5.  Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.

Authors:  Fabio Piscaglia; Sadahisa Ogasawara
Journal:  Liver Cancer       Date:  2018-01-12       Impact factor: 11.740

Review 6.  Controversies and evidence of hepatic resection for hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Guido Torzilli; Hao Xing; Chao Li; Jun Han; Lei Liang; Han Zhang; Shu-Yang Dai; Le-Qun Li; Feng Shen; Tian Yang
Journal:  BBA Clin       Date:  2016-10-11

7.  Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.

Authors:  Young-Sun Lee; Yeon Seok Seo; Ji Hoon Kim; Juneyoung Lee; Hae Rim Kim; Yang Jae Yoo; Tae Suk Kim; Seong Hee Kang; Sang Jun Suh; Moon Kyung Joo; Young Kul Jung; Beom Jae Lee; Hyung Joon Yim; Jong Eun Yeon; Jae Seon Kim; Jong-Jae Park; Soon Ho Um; Young-Tae Bak; Kwan Soo Byun
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

8.  Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients.

Authors:  Xing Li; Yan-Fang Xing; Ai-Hua Lei; Qiang Xiao; Zhi-Huan Lin; Ying-Fen Hong; Xiang-Yuan Wu; Jie Zhou
Journal:  Oncotarget       Date:  2017-04-11

9.  Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Shuling Chen; Huilin Jin; Zihao Dai; Mengchao Wei; Han Xiao; Tianhong Su; Bin Li; Xin Liu; Yu Wang; Jiaping Li; Shunli Shen; Qi Zhou; Baogang Peng; Zhenwei Peng; Sui Peng
Journal:  Cancer Med       Date:  2019-03-12       Impact factor: 4.452

10.  Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study.

Authors:  Meng Li; Yongjie Xin; Sirui Fu; Zaiyi Liu; Yong Li; Baoshan Hu; Shuting Chen; Changhong Liang; Ligong Lu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.